by Prateek Chopra | June 19, 2026 | Cardiology Conferences | ESH 2026
Clinical Context:
While the gut microbiome may influence blood pressure regulation, population-based evidence does not demonstrate a consistent link with future hypertension. Translational research is advancing our understanding of neuro-immune, inflammatory, and hormonal mechanisms in cardiovascular disease.
Key Mechanistic Insights:
Gut Microbiome: Rigorous sample collection, confounder control, and standardized analyses are essential. Metabolites such as butyrate may improve cardiac function, particularly in HFpEF.
Neuro-Immune Pathways: Brain, autonomic nervous system, spleen, and immune cells drive hypertension-related target organ damage. Neural signaling promotes inflammation, immune cell activation, and vascular infiltration, contributing to cardiovascular injury and cardiac remodeling.
Inflammation: Elevated IL-1β, TNF-α, and IFN-γ are associated with higher disease risk. T cells from patients with resistant hypertension promote hypertension, vascular dysfunction, and renal injury. TNF inhibition mitigates these effects.
Aldosterone Dysregulation and Primary Aldosteronism (PA): PA exists as a continuum from normotension to resistant hypertension. Genetic susceptibility and adrenal somatic mutations progressively increase aldosterone excess, cardiovascular risk, and overt PA.
Emerging Therapeutics:
- Baxdrostat: Produces substantial, sustained reductions in systolic BP compared with placebo.
- Persistent BP-lowering effect after treatment withdrawal, accompanied by sustained aldosterone suppression and plasma renin activity (PRA) activation, indicates a prolonged pharmacodynamic effect.
Translational research is reshaping the understanding of hypertension, highlighting neuro-immune pathways, inflammation, and aldosterone dysregulation as key drivers of cardiovascular disease. Emerging therapies such as baxdrostat provide durable BP and hormonal effects, supporting precision hypertension management strategies.